AbangeLabsFDA just cleared icotrokinra for plaque psoriasis—PSO program evidence now sets the competitive benchmark. https://www.mattheneus.com/editorial/fda-icotyde-icotrokinra-plaque-psoriasis-approval-pso-program-2026-03-17 #HTA #RegulatoryAffairs #Pharma
FDA approves ICOTYDE with a broad randomized psoriasis evidence package including active comparator data
FDA approved ICOTYDE for moderate-to-severe plaque psoriasis in adults and eligible adolescents on 17 March 2026. Label evidence from PSO-1 through PSO-4 shows robust placebo separation and active-comparator advantages versus deucravacitinib in key co-primary endpoints, creating a strong base for subsequent HTA comparative work.